Cytotoxicity of lissoclibadins and lissoclinotoxins, isolated from a tropical ascidian Lissoclinum cf. badium, against human solid-tumor-derived cell lines

Taiko Oda, Keiichi Kamoshita, Sakiko Maruyama, Kuniko Masuda, Masakazu Nishimoto, Jinzhong Xu, Kazuyo Ukai, Remy Emile Petrus Mangindaan, Michio Namikoshi

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

The in vitro growth inhibitory activity of lissoclibadins and lissoclinotoxins isolated from the tropical ascidian Lissoclinum cf. badium against nine human cancer cell lines was examined to evaluate their potential anticancer efficacy. Lissoclibadins 1 (1) and 2 (2), and lissoclinotoxin F (4) showed the strongest activity of the six compounds tested, which were more potent than the anticancer drug cisplatin. Compound 1 has a trimeric structure, and compounds 2 and 4 are structural isomers possessing dimeric structures connected by disulfide and sulfide bonds of trans- and cis-orientations, respectively. Lissoclibadin 3 (3), a dimeric compound connected by two sulfide bonds, and two monomeric compounds (5, 6) were less active than 1, 2, and 4. Lissoclibadin 2 (2) was the most interesting compound possessing potent inhibitory activity against colon (DLD-1 and HCT116), breast (MDA-MB-231), renal (ACHN), and non-small-cell lung (NCI-H460) cancer cell lines and showing no toxicity following a 50 mg/kg single treatment to mice, and preferable stability in rat plasma.

Original languageEnglish
Pages (from-to)385-387
Number of pages3
JournalBiological and Pharmaceutical Bulletin
Volume30
Issue number2
DOIs
Publication statusPublished - 2007 Feb

Fingerprint

Urochordata
Sulfides
Tumor Cell Line
Cell Line
Disulfides
Cisplatin
Neoplasms
Colon
Breast
Kidney
Lung
Growth
Pharmaceutical Preparations
In Vitro Techniques
F 4

Keywords

  • Ascidian
  • Cytotoxicity
  • Human solid-tumor cell line
  • Lissoclibadin
  • Lissoclinum cf. badium

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Cytotoxicity of lissoclibadins and lissoclinotoxins, isolated from a tropical ascidian Lissoclinum cf. badium, against human solid-tumor-derived cell lines. / Oda, Taiko; Kamoshita, Keiichi; Maruyama, Sakiko; Masuda, Kuniko; Nishimoto, Masakazu; Xu, Jinzhong; Ukai, Kazuyo; Mangindaan, Remy Emile Petrus; Namikoshi, Michio.

In: Biological and Pharmaceutical Bulletin, Vol. 30, No. 2, 02.2007, p. 385-387.

Research output: Contribution to journalArticle

Oda, Taiko ; Kamoshita, Keiichi ; Maruyama, Sakiko ; Masuda, Kuniko ; Nishimoto, Masakazu ; Xu, Jinzhong ; Ukai, Kazuyo ; Mangindaan, Remy Emile Petrus ; Namikoshi, Michio. / Cytotoxicity of lissoclibadins and lissoclinotoxins, isolated from a tropical ascidian Lissoclinum cf. badium, against human solid-tumor-derived cell lines. In: Biological and Pharmaceutical Bulletin. 2007 ; Vol. 30, No. 2. pp. 385-387.
@article{fee04ed70397462f949c19ad4b67aeed,
title = "Cytotoxicity of lissoclibadins and lissoclinotoxins, isolated from a tropical ascidian Lissoclinum cf. badium, against human solid-tumor-derived cell lines",
abstract = "The in vitro growth inhibitory activity of lissoclibadins and lissoclinotoxins isolated from the tropical ascidian Lissoclinum cf. badium against nine human cancer cell lines was examined to evaluate their potential anticancer efficacy. Lissoclibadins 1 (1) and 2 (2), and lissoclinotoxin F (4) showed the strongest activity of the six compounds tested, which were more potent than the anticancer drug cisplatin. Compound 1 has a trimeric structure, and compounds 2 and 4 are structural isomers possessing dimeric structures connected by disulfide and sulfide bonds of trans- and cis-orientations, respectively. Lissoclibadin 3 (3), a dimeric compound connected by two sulfide bonds, and two monomeric compounds (5, 6) were less active than 1, 2, and 4. Lissoclibadin 2 (2) was the most interesting compound possessing potent inhibitory activity against colon (DLD-1 and HCT116), breast (MDA-MB-231), renal (ACHN), and non-small-cell lung (NCI-H460) cancer cell lines and showing no toxicity following a 50 mg/kg single treatment to mice, and preferable stability in rat plasma.",
keywords = "Ascidian, Cytotoxicity, Human solid-tumor cell line, Lissoclibadin, Lissoclinum cf. badium",
author = "Taiko Oda and Keiichi Kamoshita and Sakiko Maruyama and Kuniko Masuda and Masakazu Nishimoto and Jinzhong Xu and Kazuyo Ukai and Mangindaan, {Remy Emile Petrus} and Michio Namikoshi",
year = "2007",
month = "2",
doi = "10.1248/bpb.30.385",
language = "English",
volume = "30",
pages = "385--387",
journal = "Biological and Pharmaceutical Bulletin",
issn = "0918-6158",
publisher = "Pharmaceutical Society of Japan",
number = "2",

}

TY - JOUR

T1 - Cytotoxicity of lissoclibadins and lissoclinotoxins, isolated from a tropical ascidian Lissoclinum cf. badium, against human solid-tumor-derived cell lines

AU - Oda, Taiko

AU - Kamoshita, Keiichi

AU - Maruyama, Sakiko

AU - Masuda, Kuniko

AU - Nishimoto, Masakazu

AU - Xu, Jinzhong

AU - Ukai, Kazuyo

AU - Mangindaan, Remy Emile Petrus

AU - Namikoshi, Michio

PY - 2007/2

Y1 - 2007/2

N2 - The in vitro growth inhibitory activity of lissoclibadins and lissoclinotoxins isolated from the tropical ascidian Lissoclinum cf. badium against nine human cancer cell lines was examined to evaluate their potential anticancer efficacy. Lissoclibadins 1 (1) and 2 (2), and lissoclinotoxin F (4) showed the strongest activity of the six compounds tested, which were more potent than the anticancer drug cisplatin. Compound 1 has a trimeric structure, and compounds 2 and 4 are structural isomers possessing dimeric structures connected by disulfide and sulfide bonds of trans- and cis-orientations, respectively. Lissoclibadin 3 (3), a dimeric compound connected by two sulfide bonds, and two monomeric compounds (5, 6) were less active than 1, 2, and 4. Lissoclibadin 2 (2) was the most interesting compound possessing potent inhibitory activity against colon (DLD-1 and HCT116), breast (MDA-MB-231), renal (ACHN), and non-small-cell lung (NCI-H460) cancer cell lines and showing no toxicity following a 50 mg/kg single treatment to mice, and preferable stability in rat plasma.

AB - The in vitro growth inhibitory activity of lissoclibadins and lissoclinotoxins isolated from the tropical ascidian Lissoclinum cf. badium against nine human cancer cell lines was examined to evaluate their potential anticancer efficacy. Lissoclibadins 1 (1) and 2 (2), and lissoclinotoxin F (4) showed the strongest activity of the six compounds tested, which were more potent than the anticancer drug cisplatin. Compound 1 has a trimeric structure, and compounds 2 and 4 are structural isomers possessing dimeric structures connected by disulfide and sulfide bonds of trans- and cis-orientations, respectively. Lissoclibadin 3 (3), a dimeric compound connected by two sulfide bonds, and two monomeric compounds (5, 6) were less active than 1, 2, and 4. Lissoclibadin 2 (2) was the most interesting compound possessing potent inhibitory activity against colon (DLD-1 and HCT116), breast (MDA-MB-231), renal (ACHN), and non-small-cell lung (NCI-H460) cancer cell lines and showing no toxicity following a 50 mg/kg single treatment to mice, and preferable stability in rat plasma.

KW - Ascidian

KW - Cytotoxicity

KW - Human solid-tumor cell line

KW - Lissoclibadin

KW - Lissoclinum cf. badium

UR - http://www.scopus.com/inward/record.url?scp=33846953920&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846953920&partnerID=8YFLogxK

U2 - 10.1248/bpb.30.385

DO - 10.1248/bpb.30.385

M3 - Article

C2 - 17268087

AN - SCOPUS:33846953920

VL - 30

SP - 385

EP - 387

JO - Biological and Pharmaceutical Bulletin

JF - Biological and Pharmaceutical Bulletin

SN - 0918-6158

IS - 2

ER -